



Final Concept Note for the Euripid Stakeholder Dialogue Platform

Version 4, after discussion at 2nd meeting on 23/09/2019

Introduction

The Grant Agreement No. 826652 of the 3rd EU Health Programme was concluded between a consortium of NEAK, GÖG, TLV, SÜKL, NOMA and Pharmeca acting on behalf of the Euripid Collaboration and CHAFEA under the powers delegated by the European Commission. The specific objective #3 refers to “Strengthening the cooperation within the EU in the field of pricing of medicinal products”. According to the grant objectives and following the joint decision at the last stakeholder meeting on 28 June 2018 in Vienna (under the previous Grant Agreement), the Euripid Collaboration intends to establish a sustainable cooperation on information exchange in the field of pricing of medicinal products in Europe with the stakeholders of the pharmaceutical sector and supranational organisations.

Aim

Strengthening the cross-functional cooperation in the field of pricing of medicinal products within the EU/EEA/EFTA as a component in order to enhance patient’s access to medicines.

Key objectives of the Dialogue Platform are

- To establish a sustainable cooperation on information exchange in the field of medicinal product pricing via the discussion of opportunities and challenges of such a cooperation.
- To further enhance the current functioning of the Euripid database.
- To monitor the implementation of the Euripid Technical Guidance Document on external reference pricing of medicinal products.
- To contribute in making pricing information on medicinal products more transparent ¹
- To investigate suitable methods to measure patients’ access to medicinal products in Europe by using the potential of, e.g. the Euripid database and website.

Target Group

The main target group of the Dialogue Platform are the previous members of the Platform on Access to Medicines in Europe² and other stakeholder organizations, particularly patient/consumer representatives, organizations like WHO and OECD, who will be invited to

¹ This includes prices.

² Under the EC Process on Corporate Social Responsibility for Medicines which included country representatives, industry associations and other interest groups (e.g., doctors associations, pharmacists) as well as EC services (http://ec.europa.eu/growth/sectors/healthcare/competitiveness/corporate-responsibility_en)



take part in the creation of a strategic cooperation in the field of pricing of medicinal products.

Mandate of the Group

- The Group shall choose the topics in the field of medicines that shall be dealt with in the meetings of the platform.
- The participation in the Platform is open to all from the target group on a strictly voluntary basis. The number of attendees per group could be limited due to available meeting room space.
- The main intention is to have a space for open and non-binding discussions (Chatham House Rule are applied). Despite, certain outcomes, jointly agreed upon, could be shared with non-group members.
- The first activities of the group included, but were not restricted,
 - to decide on the objectives, the working structure and mandate of the members of the platform as outlined in this document,
 - to explore possibilities to establish smaller working groups with the aim to achieve tangible outcomes & outputs and to establish them if necessary.

Working Structure

- Euripid will act as „secretariat” (i.e. preparation and documentation of meetings in support of the hosting organisation)
- Hosting rotation of F2F meetings among all members of the Platform, up to 2 annual meetings, perhaps piggy-backing to other events, seem reasonable. → the hosting organisation shall take care of venue, logistics and potential catering needs.
- Invitation and document Management and dissemination through a devoted Health Policy Platform Network, see <https://webgate.ec.europa.eu/hpf/network/home/79> administrated by Euripid. Every interested participant shall register there.
- Joint Development of Agenda → Establish a “Drafting Committee” that collects inputs.
- Establishment of smaller working groups, which are dedicated to mainly hold online meetings. The topics of the potential working groups will be announced on the EU Health Policy Platform. The participants of the Dialogue Platform can join voluntarily the working groups. Each working group shall have at least one dedicated facilitator.

Main topics for discussion jointly decided by the Group are

Transparency of Prices: Pros and Cons

Real Patient Access (Affordability, availability and how to avoid shortages) – from which perspective

Monitoring the uptake of Euripid database and namely the ERP Technical Guidance Document